Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation
South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of d...
Gespeichert in:
| Veröffentlicht in: | Diabetic medicine 2021-04, Vol.38 (4), p.e14497-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 |
| container_start_page | e14497 |
| container_title | Diabetic medicine |
| container_volume | 38 |
| creator | Hanif, Wasim Ali, Sarah N Bellary, Srikanth Patel, Vinod Farooqi, Azhar Karamat, Muhammad Ali Saeed, Mujahid Sivaprasad, Sobha Patel, Kiran Khunti, Kamlesh |
| description | South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre‐diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence‐based, cost‐effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1]. |
| doi_str_mv | 10.1111/dme.14497 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2483407460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2483407460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-c3e87d9ff80cce4215e029734e8a6b0c69478d4d7010452b505b579dfb4d1a553</originalsourceid><addsrcrecordid>eNp1kV1LHDEUhkNR6mp70T9QAt7oxWo-J5PeyfoJSgttr0MmOeOOTCbbZAbZy_5zo7sVKZiLk5zwnIeQF6EvlJzQsk59gBMqhFYf0IyKSsyl0HQHzYgSbM6JontoP-cHQijTXH9Ee5xzQismZ-jvj6VNwbrYx_vO2R4HO9h7CDCMOLb4Z5zGJT7LnR0yfuzKeVyvADPsO9vACPkbXsQhw5CnjBO4GMqkt2NXLnGbYsDjEt5a8DXYvjSXcdpyn9Bua_sMn7f7Afp9efFrcT2__X51szi7nTte16pUqJXXbVsT50AwKoEwrbiA2lYNcZUWqvbCK0KJkKyRRDZSad82wlMrJT9ARxvvKsU_E-TRhC476Hs7QJyyYaLmovxYRQp6-B_6EKc0lNcZJolmnFWSFup4Q7kUc07QmlXqgk1rQ4l5zsWUXMxLLoX9ujVOTQD_Sv4LogCnG-Cx62H9vsmc311slE9DIpdK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509232651</pqid></control><display><type>article</type><title>Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hanif, Wasim ; Ali, Sarah N ; Bellary, Srikanth ; Patel, Vinod ; Farooqi, Azhar ; Karamat, Muhammad Ali ; Saeed, Mujahid ; Sivaprasad, Sobha ; Patel, Kiran ; Khunti, Kamlesh</creator><creatorcontrib>Hanif, Wasim ; Ali, Sarah N ; Bellary, Srikanth ; Patel, Vinod ; Farooqi, Azhar ; Karamat, Muhammad Ali ; Saeed, Mujahid ; Sivaprasad, Sobha ; Patel, Kiran ; Khunti, Kamlesh</creatorcontrib><description>South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre‐diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence‐based, cost‐effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.14497</identifier><identifier>PMID: 33301625</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Afghanistan - epidemiology ; Asia - epidemiology ; Asian people ; Asians - statistics & numerical data ; Bangladesh - epidemiology ; Best practice ; Bhutan - epidemiology ; cardiovascular disease ; Cardiovascular diseases ; cardiovascular outcome trials ; Clinical practice guidelines ; Consensus ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - ethnology ; Diabetes Mellitus, Type 2 - therapy ; Disease management ; Drug therapy ; glucagon‐like peptide‐1 receptor agonists ; Health risks ; Humans ; India - epidemiology ; Indian Ocean Islands - epidemiology ; Nepal - epidemiology ; Pakistan - epidemiology ; practice guidelines ; Practice Guidelines as Topic ; Societies, Medical - standards ; sodium‐glucose transporter 2 inhibitors ; South Asians ; Sri Lanka - epidemiology ; type 2 diabetes</subject><ispartof>Diabetic medicine, 2021-04, Vol.38 (4), p.e14497-n/a</ispartof><rights>2020 Diabetes UK</rights><rights>2020 Diabetes UK.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-c3e87d9ff80cce4215e029734e8a6b0c69478d4d7010452b505b579dfb4d1a553</citedby><cites>FETCH-LOGICAL-c3887-c3e87d9ff80cce4215e029734e8a6b0c69478d4d7010452b505b579dfb4d1a553</cites><orcidid>0000-0003-2343-7099</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdme.14497$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdme.14497$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33301625$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hanif, Wasim</creatorcontrib><creatorcontrib>Ali, Sarah N</creatorcontrib><creatorcontrib>Bellary, Srikanth</creatorcontrib><creatorcontrib>Patel, Vinod</creatorcontrib><creatorcontrib>Farooqi, Azhar</creatorcontrib><creatorcontrib>Karamat, Muhammad Ali</creatorcontrib><creatorcontrib>Saeed, Mujahid</creatorcontrib><creatorcontrib>Sivaprasad, Sobha</creatorcontrib><creatorcontrib>Patel, Kiran</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><title>Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation</title><title>Diabetic medicine</title><addtitle>Diabet Med</addtitle><description>South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre‐diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence‐based, cost‐effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].</description><subject>Afghanistan - epidemiology</subject><subject>Asia - epidemiology</subject><subject>Asian people</subject><subject>Asians - statistics & numerical data</subject><subject>Bangladesh - epidemiology</subject><subject>Best practice</subject><subject>Bhutan - epidemiology</subject><subject>cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>cardiovascular outcome trials</subject><subject>Clinical practice guidelines</subject><subject>Consensus</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - ethnology</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Disease management</subject><subject>Drug therapy</subject><subject>glucagon‐like peptide‐1 receptor agonists</subject><subject>Health risks</subject><subject>Humans</subject><subject>India - epidemiology</subject><subject>Indian Ocean Islands - epidemiology</subject><subject>Nepal - epidemiology</subject><subject>Pakistan - epidemiology</subject><subject>practice guidelines</subject><subject>Practice Guidelines as Topic</subject><subject>Societies, Medical - standards</subject><subject>sodium‐glucose transporter 2 inhibitors</subject><subject>South Asians</subject><subject>Sri Lanka - epidemiology</subject><subject>type 2 diabetes</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1LHDEUhkNR6mp70T9QAt7oxWo-J5PeyfoJSgttr0MmOeOOTCbbZAbZy_5zo7sVKZiLk5zwnIeQF6EvlJzQsk59gBMqhFYf0IyKSsyl0HQHzYgSbM6JontoP-cHQijTXH9Ee5xzQismZ-jvj6VNwbrYx_vO2R4HO9h7CDCMOLb4Z5zGJT7LnR0yfuzKeVyvADPsO9vACPkbXsQhw5CnjBO4GMqkt2NXLnGbYsDjEt5a8DXYvjSXcdpyn9Bua_sMn7f7Afp9efFrcT2__X51szi7nTte16pUqJXXbVsT50AwKoEwrbiA2lYNcZUWqvbCK0KJkKyRRDZSad82wlMrJT9ARxvvKsU_E-TRhC476Hs7QJyyYaLmovxYRQp6-B_6EKc0lNcZJolmnFWSFup4Q7kUc07QmlXqgk1rQ4l5zsWUXMxLLoX9ujVOTQD_Sv4LogCnG-Cx62H9vsmc311slE9DIpdK</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Hanif, Wasim</creator><creator>Ali, Sarah N</creator><creator>Bellary, Srikanth</creator><creator>Patel, Vinod</creator><creator>Farooqi, Azhar</creator><creator>Karamat, Muhammad Ali</creator><creator>Saeed, Mujahid</creator><creator>Sivaprasad, Sobha</creator><creator>Patel, Kiran</creator><creator>Khunti, Kamlesh</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2343-7099</orcidid></search><sort><creationdate>202104</creationdate><title>Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation</title><author>Hanif, Wasim ; Ali, Sarah N ; Bellary, Srikanth ; Patel, Vinod ; Farooqi, Azhar ; Karamat, Muhammad Ali ; Saeed, Mujahid ; Sivaprasad, Sobha ; Patel, Kiran ; Khunti, Kamlesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-c3e87d9ff80cce4215e029734e8a6b0c69478d4d7010452b505b579dfb4d1a553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Afghanistan - epidemiology</topic><topic>Asia - epidemiology</topic><topic>Asian people</topic><topic>Asians - statistics & numerical data</topic><topic>Bangladesh - epidemiology</topic><topic>Best practice</topic><topic>Bhutan - epidemiology</topic><topic>cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>cardiovascular outcome trials</topic><topic>Clinical practice guidelines</topic><topic>Consensus</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - ethnology</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Disease management</topic><topic>Drug therapy</topic><topic>glucagon‐like peptide‐1 receptor agonists</topic><topic>Health risks</topic><topic>Humans</topic><topic>India - epidemiology</topic><topic>Indian Ocean Islands - epidemiology</topic><topic>Nepal - epidemiology</topic><topic>Pakistan - epidemiology</topic><topic>practice guidelines</topic><topic>Practice Guidelines as Topic</topic><topic>Societies, Medical - standards</topic><topic>sodium‐glucose transporter 2 inhibitors</topic><topic>South Asians</topic><topic>Sri Lanka - epidemiology</topic><topic>type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hanif, Wasim</creatorcontrib><creatorcontrib>Ali, Sarah N</creatorcontrib><creatorcontrib>Bellary, Srikanth</creatorcontrib><creatorcontrib>Patel, Vinod</creatorcontrib><creatorcontrib>Farooqi, Azhar</creatorcontrib><creatorcontrib>Karamat, Muhammad Ali</creatorcontrib><creatorcontrib>Saeed, Mujahid</creatorcontrib><creatorcontrib>Sivaprasad, Sobha</creatorcontrib><creatorcontrib>Patel, Kiran</creatorcontrib><creatorcontrib>Khunti, Kamlesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hanif, Wasim</au><au>Ali, Sarah N</au><au>Bellary, Srikanth</au><au>Patel, Vinod</au><au>Farooqi, Azhar</au><au>Karamat, Muhammad Ali</au><au>Saeed, Mujahid</au><au>Sivaprasad, Sobha</au><au>Patel, Kiran</au><au>Khunti, Kamlesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet Med</addtitle><date>2021-04</date><risdate>2021</risdate><volume>38</volume><issue>4</issue><spage>e14497</spage><epage>n/a</epage><pages>e14497-n/a</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><abstract>South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre‐diabetes and cardiovascular diseases’ offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence‐based, cost‐effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33301625</pmid><doi>10.1111/dme.14497</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-2343-7099</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0742-3071 |
| ispartof | Diabetic medicine, 2021-04, Vol.38 (4), p.e14497-n/a |
| issn | 0742-3071 1464-5491 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2483407460 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Afghanistan - epidemiology Asia - epidemiology Asian people Asians - statistics & numerical data Bangladesh - epidemiology Best practice Bhutan - epidemiology cardiovascular disease Cardiovascular diseases cardiovascular outcome trials Clinical practice guidelines Consensus Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - ethnology Diabetes Mellitus, Type 2 - therapy Disease management Drug therapy glucagon‐like peptide‐1 receptor agonists Health risks Humans India - epidemiology Indian Ocean Islands - epidemiology Nepal - epidemiology Pakistan - epidemiology practice guidelines Practice Guidelines as Topic Societies, Medical - standards sodium‐glucose transporter 2 inhibitors South Asians Sri Lanka - epidemiology type 2 diabetes |
| title | Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T02%3A10%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20management%20of%20South%20Asians%20with%20type%202%20diabetes:%20Consensus%20recommendations%20from%20the%20South%20Asian%20Health%20Foundation&rft.jtitle=Diabetic%20medicine&rft.au=Hanif,%20Wasim&rft.date=2021-04&rft.volume=38&rft.issue=4&rft.spage=e14497&rft.epage=n/a&rft.pages=e14497-n/a&rft.issn=0742-3071&rft.eissn=1464-5491&rft_id=info:doi/10.1111/dme.14497&rft_dat=%3Cproquest_cross%3E2483407460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509232651&rft_id=info:pmid/33301625&rfr_iscdi=true |